Scorpion Therapeutics Inc. has found compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
Researchers from Vividion Therapeutics Inc. and partner Roche Holdings AG have published the discovery and preclinical characterization of the novel covalent allosteric inhibitor of WRN, VVD-133214 (RO-7589831).
Fogpharma Inc. and Artbio Inc. have established a collaboration to co-develop a new class of α-radioligand therapeutics to maximize efficacy for patients with multiple types of cancer.
Pheast Therapeutics Inc. has announced the presentation of preclinical data for PHST-001, a therapeutic monoclonal antibody targeting CD24, a macrophage checkpoint.
At last week’s ASGCT meeting, Adicet Bio Inc. presented a new CAR T-cell therapy, ADI-270, for the treatment of CD70-expressing tumors. ADI-270 uses CD27 as the binding domain and 4-1BB co-stimulatory domains plus CD3.
Aurigene Oncology Ltd. has disclosed new bicyclic heteroaryl compounds acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors potentially useful for the treatment of cancer.
Dana-Farber Cancer Institute Inc. has identified alkylamine-containing small-molecule B-cell lymphoma 6 protein (BCL6) degradation inducers potentially useful for the treatment of lymphoma.
Researchers from Tokyo Medical University presented data from a study that assessed microRNA (miRNA) profiles in extracellular vesicles (EVs) isolated from vitreous humor and serum of patients with ocular sarcoidosis and vitreoretinal lymphoma (VRL).